Published in the Journal of Diabetes Research, new research highlights the therapeutic potential of an engineered self-assembling peptide, MYR-DM-ANG1-7. It is designed to address the dual challenges of infection and impaired vascular repair in diabetic wounds.

The peptide was developed by modifying an amphibian-derived antimicrobial peptide (DM) with a myristoyl group at the N-terminus and conjugating ANG1-7 at the C-terminus via a flexible linker. Structural analyses confirmed its purity and stability. The modified peptide forms micelles approximately 22 nm in size. This design enhanced both protease resistance and antibacterial activity.

Laboratory tests revealed low cytotoxicity, minimal hemolysis, and high biocompatibility. MYR-DM-ANG1-7 displayed strong antibacterial effects against Staphylococcus aureus and Escherichia coli, with minimal inhibitory concentrations of 16 μg/mL and 12 μg/mL, respectively. It also inhibited biofilm formation, a major barrier in chronic wound infections.

In vivo, the peptide demonstrated excellent organ safety and promoted wound healing in a diabetic mouse model. Treatment reduced bacterial load, restored epidermal thickness, and enhanced collagen deposition. Immunofluorescence confirmed improved vascular regeneration, driven by activation of the PI3K/AKT/eNOS pathway through Mas receptor binding.

By integrating antimicrobial action with proangiogenic activity, MYR-DM-ANG1-7 addresses two critical aspects of diabetic wound pathology- persistent infection and angiogenesis. While further studies on long-term resistance and immunomodulation are needed, the findings suggest strong potential for clinical translation. This modular peptide design may represent a next-generation therapy to reduce infection-related complications and amputation risks in patients with diabetic wounds.